---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117755"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:54:26.672648+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics reports Q3 net loss $6.6M; announces public offering of 5M shares at $1.20

## Summary
- Public offering of 5,000,000 shares at $1.20/share; gross proceeds $6.0M; net ~$5.4M; underwriter option for 750k additional shares.
- Q3 2022 net loss $6.6M ($0.29 diluted) vs $4.9M ($8.12) in Q3 2021; R&D expense $8.3M, G&A $4.4M.
- Cash $46.6M at Sept 30; $93.6M in awarded grants remain available; cash runway extended into first half 2024.
- Lead candidate CT1812 in three Phase 2 trials: SHINE expands to Europe, SEQUEL gets additional NIA grant, SHIMMER sites activating.

## SEC filing metadata
- accession: 0001104659-22-117755
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465922117755/0001104659-22-117755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465922117755/tm2230367d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117755
- JSON: https://secwatch.observer/filing/0001104659-22-117755.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117755.txt

## Key facts
- Earnings Releases
  COGNITION THERAPEUTICS INC reported third quarter ended September 30, 2022 results: net income $6.6 million, EPS $0.29 per share.
  - Period: third quarter ended September 30, 2022
  - Net income: $6.6 million
  - EPS: $0.29 per share
  - Result: reported results
  source text: Net loss attributable to common stockholders for the third quarter ended September 30, 2022, was $6.6 million or $0.29 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465922117755/0001104659-22-117755-index.htm
- Material Agreements
  COGNITION THERAPEUTICS INC entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at 5,000,000 shares of common stock at $1.20 per share (effective 2022-11-10).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: 5,000,000 shares of common stock at $1.20 per share
  - Effective: 2022-11-10
  source text: On November 10, 2022, Cognition Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co., as representative of the several underwriters named in Schedule A thereto (the “Underwriters”), relating to the public offering (the “Offering”) of 5,000,000 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), at a price to the public of $1.20 per share (the “Offering Price”), less underwriting discounts and commissions.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465922117755/0001104659-22-117755-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.